Field Medical Secures $35 Million Series B Funding for Heart Ablation Technology Development
In a significant milestone for cardiac treatment innovation, Field Medical, Inc. has successfully concluded a $35 million Series B funding round, highlighting the company's commitment to pushing forward its FieldForce™ Pulsed Field Ablation (PFA) platform. This funding, spearheaded by BioStar Capital and Cue Growth, aims to support the company in accelerating its preparations for regulatory approval trials, specifically targeting the treatment of ventricular tachycardia (VT).
Field Medical, established as a clinical-stage company, is redefining heart ablation methodologies with its next-generation technology designed for precision and speed in creating transmural lesions. This initiative is not only pivotal for the company but also positions it at the forefront of a relatively uncharted segment in electrophysiology. The company's recent pilot data, unveiled at the 2025 Heart Rhythm Society conference, played a crucial role in attracting this round of investment.
As per Steven Mickelsen, MD, the Founder and CEO of Field Medical, the market for VT therapy symbolizes an area of immense clinical demand, which is currently underserved by existing tools. He asserts that the introduction of a novel therapy can meet this critical need, emphasizing the speed, precision, and clinical advancement that Field Medical aims to deliver through its technology.
This Series B funding marks a cumulative total of $75 million raised by Field Medical to date, a testament to its strong leadership in PFA advancements for complex arrhythmias. Dr. Louis Cannon, Founder and Senior Managing Director of BioStar Capital, has voiced support for Field Medical, praising its innovative tackle on one of the most challenging issues in cardiology with genuine urgency and insight.
In light of the company's rapid growth trajectory, Field Medical is expanding its board of directors. This update features several key appointments:
Founded in 2022, Field Medical focuses on developing PFA technologies for the treatment of complex heart rhythm disorders. The FieldForce™ Ablation System merges groundbreaking catheter design with patent-pending FieldBending™ energy, which is engineered for rapid and targeted ablation.
In recognition of its innovative efforts, Field Medical received Breakthrough Device Designation in 2024 and was chosen for the FDA’s TAP Pilot Program for its VT indication. The company is dedicated to reshaping VT care for high-risk patients and is enthusiastic about the potential for its therapies to redefine existing standards.
Further insights and updates on the company's clinical focus and technology can be accessed via their website or through their social media channels. It’s clear that Field Medical is making notable strides in the medical technology landscape, with promising implications for patient's lives nationwide.
Field Medical, established as a clinical-stage company, is redefining heart ablation methodologies with its next-generation technology designed for precision and speed in creating transmural lesions. This initiative is not only pivotal for the company but also positions it at the forefront of a relatively uncharted segment in electrophysiology. The company's recent pilot data, unveiled at the 2025 Heart Rhythm Society conference, played a crucial role in attracting this round of investment.
As per Steven Mickelsen, MD, the Founder and CEO of Field Medical, the market for VT therapy symbolizes an area of immense clinical demand, which is currently underserved by existing tools. He asserts that the introduction of a novel therapy can meet this critical need, emphasizing the speed, precision, and clinical advancement that Field Medical aims to deliver through its technology.
This Series B funding marks a cumulative total of $75 million raised by Field Medical to date, a testament to its strong leadership in PFA advancements for complex arrhythmias. Dr. Louis Cannon, Founder and Senior Managing Director of BioStar Capital, has voiced support for Field Medical, praising its innovative tackle on one of the most challenging issues in cardiology with genuine urgency and insight.
In light of the company's rapid growth trajectory, Field Medical is expanding its board of directors. This update features several key appointments:
- - Steven Mickelsen, MD, will continue to lead the company with his extensive background in electrophysiology and entrepreneurship.
- - Mark Wisniewski, CFO from Enterra Medical, brings his comprehensive expertise in mergers and acquisitions to the board.
- - Marlou Janssen, an experienced executive with significant contributions to the cardiology and emerging med-tech sectors, is also joining the board.
- - Alexei Mlodinow, MD, MBA, a surgeon and serial entrepreneur known for his successes in medical tech, will lend his expertise to the board.
- - Ben Cannon, a founding partner at Cue Growth, offers insights from his vast experience scaling growth-stage companies.
Founded in 2022, Field Medical focuses on developing PFA technologies for the treatment of complex heart rhythm disorders. The FieldForce™ Ablation System merges groundbreaking catheter design with patent-pending FieldBending™ energy, which is engineered for rapid and targeted ablation.
In recognition of its innovative efforts, Field Medical received Breakthrough Device Designation in 2024 and was chosen for the FDA’s TAP Pilot Program for its VT indication. The company is dedicated to reshaping VT care for high-risk patients and is enthusiastic about the potential for its therapies to redefine existing standards.
Further insights and updates on the company's clinical focus and technology can be accessed via their website or through their social media channels. It’s clear that Field Medical is making notable strides in the medical technology landscape, with promising implications for patient's lives nationwide.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.